Chimeric Derivatives of Hepatitis B Virus Core Particles Carrying Major Epitopes of the Rubella Virus E1 Glycoprotein | Zendy

Dace Skrastiņa | Zendy; Ivars Petrovskis | Zendy; Rasa Petraitytė-Burneikienė | Zendy; Irina Sominskaya | Zendy; Velta Ose | Zendy; I. Lieknina | Zendy; Jānis Bogans | Zendy; Kęstutis Sasnauskas | Zendy; Paul Pumpens | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Chimeric Derivatives of Hepatitis B Virus Core Particles Carrying Major Epitopes of the Rubella Virus E1 Glycoprotein

Author(s) -

Dace Skrastiņa,

Ivars Petrovskis,

Rasa Petraitytė-Burneikienė,

Irina Sominskaya,

Velta Ose,

I. Lieknina,

Jānis Bogans,

Kęstutis Sasnauskas,

Paul Pumpens

Publication year - 2013

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00533-13

Subject(s) - virology , rubella virus , epitope , glycoprotein , virus , biology , rubella , antibody , vaccination , genetics , measles

Three variants of the major rubella virus (RV) E1 protein virus-neutralizing epitope from position 214 to 285 were exposed on the hepatitis B virus (HBV) C-terminally truncated core (HBcΔ) in a virus-like particle (VLP) vector and were produced inEscherichia coli . All three chimeras demonstrated VLPs in bacterial cell lysates, but only HBcΔ-E1(245-285) demonstrated the correct VLP structure after purification. The other chimeras, HBcΔ-E1(214-285) and HBcΔ-E1(214-240), appeared after purification as non-VLP aggregates of 100 to 900 nm in diameter according to dynamic light scattering data. All three variants possessed the intrinsic antigenic activity of RV E1, since they were recognized by natural human anti-RV E1 antibodies and induced an anti-RV E1 response in mice. HBcΔ-E1(214-240) and HBcΔ-E1(245-285) can be regarded as prototypes for a putative RV vaccine because they were able to induce antibodies recognizing natural RV E1 protein in RV diagnostic kits.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research